PA8481901A1 - ADMINISTRATION OF ACTIVE AGENT IN DRY POWDER - Google Patents

ADMINISTRATION OF ACTIVE AGENT IN DRY POWDER

Info

Publication number
PA8481901A1
PA8481901A1 PA19998481901A PA8481901A PA8481901A1 PA 8481901 A1 PA8481901 A1 PA 8481901A1 PA 19998481901 A PA19998481901 A PA 19998481901A PA 8481901 A PA8481901 A PA 8481901A PA 8481901 A1 PA8481901 A1 PA 8481901A1
Authority
PA
Panama
Prior art keywords
active agent
administration
dry powder
inhibitor
hygroscopic growth
Prior art date
Application number
PA19998481901A
Other languages
Spanish (es)
Inventor
Barry John Aldous
Andrew Clark
Kuo Mei Chang
Cecily Lalor
Original Assignee
Inhale Therapeutic Syst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inhale Therapeutic Syst filed Critical Inhale Therapeutic Syst
Publication of PA8481901A1 publication Critical patent/PA8481901A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)

Abstract

PARTICULAS PARA LA ADMINISTRACION DE UN AGENTE ACTIVO A LOS ALVEOLOS DE UN PACIENTE HUMANO, PARTICULAS QUE CONTIENEN EL AGENTE ACTIVO Y UN INHIBIDOR DEL CRECIMIENTO HIGROSCOPICO, DONDE EL INHIBIDOR DEL CRECIMIENTO HIGROSCOPICO ESTA INCORPORADO AL INTERIOR DE LAS PARTICULAS Y DONDE LAS PARTICULAS EXHIBEN UNA CAIDA DE LA DOSIS EMITIDA, EN CONDICIONES PULMONARES SIMULADAS, DE NO MAS DE APROXIMADAMENTE 25%.PARTICLES FOR THE ADMINISTRATION OF AN ACTIVE AGENT TO THE HELLS OF A HUMAN PATIENT, PARTICLES CONTAINING THE ACTIVE AGENT AND AN INHIBITOR OF HYGROSCOPIC GROWTH, WHERE THE INHIBITOR OF HYGROSCOPIC GROWTH IS INCORPORATED TO THE INSIDE OF PARTICULAS THE DOSE ISSUED, IN SIMULATED PULMONARY CONDITIONS, OF NO MORE THAN APPROXIMATELY 25%.

PA19998481901A 1998-09-14 1999-09-14 ADMINISTRATION OF ACTIVE AGENT IN DRY POWDER PA8481901A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10016398P 1998-09-14 1998-09-14

Publications (1)

Publication Number Publication Date
PA8481901A1 true PA8481901A1 (en) 2002-04-25

Family

ID=22278404

Family Applications (1)

Application Number Title Priority Date Filing Date
PA19998481901A PA8481901A1 (en) 1998-09-14 1999-09-14 ADMINISTRATION OF ACTIVE AGENT IN DRY POWDER

Country Status (44)

Country Link
EP (1) EP1117442A1 (en)
JP (1) JP2002524535A (en)
KR (1) KR20010075063A (en)
CN (1) CN1317977A (en)
AP (1) AP1374A (en)
AR (1) AR022090A1 (en)
AU (1) AU753014B2 (en)
BG (1) BG105430A (en)
BR (1) BR9913722A (en)
CA (1) CA2343920A1 (en)
CO (1) CO5130023A1 (en)
CZ (1) CZ2001829A3 (en)
DZ (1) DZ2892A1 (en)
EA (1) EA003476B1 (en)
EE (1) EE200100151A (en)
GE (1) GEP20043257B (en)
GT (1) GT199900156A (en)
HK (1) HK1042231A1 (en)
HN (1) HN1999000159A (en)
HR (1) HRP20010189A2 (en)
HU (1) HUP0103837A3 (en)
ID (1) ID28845A (en)
IL (2) IL141562A0 (en)
IS (1) IS5878A (en)
LT (1) LT4897B (en)
LV (1) LV12658B (en)
MA (1) MA25590A1 (en)
MY (1) MY129282A (en)
NO (1) NO20011251L (en)
NZ (1) NZ510168A (en)
OA (1) OA11781A (en)
PA (1) PA8481901A1 (en)
PE (1) PE20001061A1 (en)
PL (1) PL195574B1 (en)
SA (1) SA99200718B1 (en)
SK (1) SK3442001A3 (en)
TN (1) TNSN99173A1 (en)
TR (1) TR200101182T2 (en)
TW (1) TWI226248B (en)
UA (1) UA76085C2 (en)
UY (1) UY25711A1 (en)
WO (1) WO2000015262A1 (en)
YU (1) YU24201A (en)
ZA (1) ZA200101995B (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000075281A2 (en) 1999-06-09 2000-12-14 University Technology Corporation Supercritical fluid-assisted nebulization and bubble drying
US6475468B2 (en) * 2001-02-15 2002-11-05 Aeropharm Technology Incorporated Modulated release particles for aerosol delivery
EP1392262A1 (en) * 2001-05-24 2004-03-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
EG24184A (en) 2001-06-15 2008-10-08 Otsuka Pharma Co Ltd Dry powder inhalation system for transpulmonary
US7759506B2 (en) 2002-02-25 2010-07-20 Diffusion Pharmaceuticals Llc Bipolar trans carotenoid salts and their uses
CZ2004904A3 (en) 2002-02-25 2004-12-15 Diffusion Pharmaceuticals Llc Bipolar carotenoid salts and use thereof
AU2003232081B2 (en) * 2002-07-03 2009-02-05 Brandeis University Central airway administration for systemic delivery of therapeutics
MXPA05006802A (en) * 2002-12-19 2005-09-08 Pharmacia Corp Non-hygroscopic formulation comprising a hydroscopic drug.
DE10338403A1 (en) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Powder formulation containing the CGRP antagonist 1- [N 2 - [3,5-dibromo-N - [[4- (3,4-dihydro-2 (1 H) -oxoquinazolin-3-yl] -1-piperidinyl] carbonyl] -D-tyrosyl] -L-lysyl] -4- (4-pyrindinyl) piperazine, process for its preparation and its use as inhalant
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
WO2005104712A2 (en) * 2004-04-23 2005-11-10 Cydex, Inc. Dpi formulation containing sulfoalkyl ether cyclodextrin
CN104840455A (en) 2005-02-24 2015-08-19 扩散药品有限公司 Trans carotenoids, their synthesis, formulation and uses
AU2006221364A1 (en) * 2005-03-09 2006-09-14 Ono Pharmaceutical Co., Ltd. Particle and preparation containing the particle
US7629331B2 (en) 2005-10-26 2009-12-08 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
PL2581078T3 (en) 2005-10-26 2015-07-31 Cydex Pharmaceuticals Inc Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
US20080035143A1 (en) * 2006-08-14 2008-02-14 Sievers Robert E Human-powered dry powder inhaler and dry powder inhaler compositions
WO2008050847A1 (en) * 2006-10-25 2008-05-02 Dainippon Sumitomo Pharma Co., Ltd. Granular preparation prevented from caking
EP1925295A1 (en) * 2006-11-22 2008-05-28 Boehringer Ingelheim Pharma GmbH & Co. KG Stable powder formulation containing a new antichinolinergic agent
EP2146948A4 (en) 2007-04-13 2010-08-04 Diffusion Pharmaceuticals Llc Use of bipolar trans carotenoids as a pretreatment and in the treatment of peripheral vascular disease
MX2010004803A (en) 2007-10-31 2010-09-09 Diffusion Pharmaceuticals Llc A new class of therapeutics that enhance small molecule diffusion.
PL2432502T3 (en) 2009-05-20 2018-05-30 Aeras Stable, spray dried, immunogenic, viral compositions
EP2445339B1 (en) 2009-06-22 2019-08-07 Diffusion Pharmaceuticals LLC Diffusion enhancing compound and its use with a thrombolytic
CN103124498A (en) 2010-06-02 2013-05-29 扩散药品有限公司 Oral formulations of bipolar trans carotenoids
KR102240042B1 (en) 2012-05-03 2021-04-14 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 Polyinosinic-polycytidylic acid (poly (i:c)) formulations for the treatment of upper respiratory tract infections
WO2014074797A1 (en) * 2012-11-09 2014-05-15 Civitas Therapeutics, Inc. Ultra low density pulmonary powders
WO2015042352A1 (en) * 2013-09-20 2015-03-26 Virginia Commonwealth University Delivery of particles using hygroscopic excipients
MX2017005692A (en) 2014-10-31 2017-08-07 Glaxosmithkline Ip Dev Ltd Powder formulation.
KR102489034B1 (en) 2016-03-24 2023-01-13 디퓨젼 파마슈티컬즈 엘엘씨 Use of Bipolar Trans Carotenoids with Chemotherapy and Radiation Therapy to Treat Cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3155573A (en) * 1958-05-06 1964-11-03 Benger Lab Ltd Inhalant composition and method of making same
DE69332240T2 (en) * 1992-06-12 2003-04-10 Teijin Ltd ULTRA FINE POWDER FOR INHALATION AND PRODUCTION
US6524557B1 (en) * 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
ES2236832T3 (en) * 1997-01-16 2005-07-16 Massachusetts Institute Of Technology PREPARATION OF PARTICLES FOR INHALATION.
US6086376A (en) * 1998-01-30 2000-07-11 Rtp Pharma Inc. Dry aerosol suspension of phospholipid-stabilized drug microparticles in a hydrofluoroalkane propellant

Also Published As

Publication number Publication date
AR022090A1 (en) 2002-09-04
LT2001021A (en) 2001-11-26
IL141562A (en) 2007-07-24
GT199900156A (en) 2001-03-07
DZ2892A1 (en) 2003-12-15
CN1317977A (en) 2001-10-17
UY25711A1 (en) 1999-11-17
CO5130023A1 (en) 2002-02-27
LV12658A (en) 2001-05-20
PL195574B1 (en) 2007-10-31
AP2001002093A0 (en) 2001-03-31
BG105430A (en) 2001-12-29
HN1999000159A (en) 1999-11-11
EP1117442A1 (en) 2001-07-25
HK1042231A1 (en) 2002-08-09
NO20011251L (en) 2001-04-17
PL346768A1 (en) 2002-02-25
CA2343920A1 (en) 2000-03-23
EA003476B1 (en) 2003-06-26
LV12658B (en) 2001-09-20
HUP0103837A2 (en) 2002-05-29
TWI226248B (en) 2005-01-11
ZA200101995B (en) 2002-03-11
CZ2001829A3 (en) 2001-09-12
TNSN99173A1 (en) 2005-11-10
ID28845A (en) 2001-07-05
AU753014B2 (en) 2002-10-03
MY129282A (en) 2007-03-30
LT4897B (en) 2002-02-25
YU24201A (en) 2003-08-29
NO20011251D0 (en) 2001-03-13
HRP20010189A2 (en) 2005-04-30
SK3442001A3 (en) 2001-11-06
NZ510168A (en) 2003-09-26
OA11781A (en) 2005-07-26
EE200100151A (en) 2002-06-17
KR20010075063A (en) 2001-08-09
HUP0103837A3 (en) 2002-11-28
AU6039799A (en) 2000-04-03
GEP20043257B (en) 2004-06-25
SA99200718B1 (en) 2006-11-04
JP2002524535A (en) 2002-08-06
PE20001061A1 (en) 2000-10-08
BR9913722A (en) 2001-05-29
WO2000015262A1 (en) 2000-03-23
IS5878A (en) 2001-03-05
IL141562A0 (en) 2002-03-10
UA76085C2 (en) 2006-07-17
MA25590A1 (en) 2002-12-31
TR200101182T2 (en) 2001-09-21
AP1374A (en) 2005-02-28
EA200100300A1 (en) 2001-10-22

Similar Documents

Publication Publication Date Title
PA8481901A1 (en) ADMINISTRATION OF ACTIVE AGENT IN DRY POWDER
AR020760A1 (en) DEVICE FOR CONTROLLING THE ADMINISTRATION OF AN ACTIVE AGENT IN AEROSOL IN THE LUNGS OF A HUMAN PATIENT
CO5060522A1 (en) ADMINISTRATION OF AN ACTIVE AGENT IN AEROSOL
ES2159591T3 (en) COMPOSITION OF CONTROLLED RELEASE.
GT200000041A (en) USE OF CYP2D6 INHIBITORS IN COMBINATION THERAPIES.
ES2073205T3 (en) AGENTS WITH PHYSIOLOGICAL REFRIGERATING EFFECT AND PROPER ACTIVE COMPOUNDS FOR THESE AGENTS.
ES2117015T3 (en) COMPOSITIONS CONTAINING SUMATRIPTAN.
DE3382458D1 (en) HAIR GROWTH AGENT.
ES2064121T3 (en) AGENT TO REDUCE OR ELIMINATE THE GROWTH OF HAIR IN THE HUMAN BODY.
MX9300620A (en) PHARMACEUTICAL FORMULATION IN AEROSOL AND INHALER FOR THE ADMINISTRATION OF BECLOMETASONE DIPROPIONATE.
ES2185817T3 (en) ORAL PHARMACEUTICAL DOSAGE FORMS THAT INCLUDE AN INHIBITOR OF THE PUMPS OF PROTONS AND AN AGENT ANTICIDE OR ALGINATE.
BRPI0408655A (en) formulations comprising an active agent and cocoa powder and their use
DE69620606T2 (en) FIXED ORAL APPLICATION FORM
BR0311460A (en) Modified release pharmaceutical composition, use of a formulation, and method for treating a cardiovascular disorder in a patient
NO951498L (en) Pharmaceutical preparation for the treatment of osteoporosis
ES2184145T3 (en) SULPHONIC ACID OR SULFONYLAMINE ACIDS-N- (HETEROARALQUIL) -AZAHETEROCICLILAMIDA.
AR024998A1 (en) NEW RETINOIDS FOR THE TREATMENT OF THE DISEASE
CN111214689A (en) Sachet for efficiently preventing novel coronavirus pneumonia and influenza
EA200200151A1 (en) DRY POWDER COMPOSITION
AR021086A1 (en) OMEGA-AMIDAS OF N-ARILSULFONIL-AMINO ACIDS, A PROCEDURE FOR THE PREPARATION, MEDICATION, USE OF SUCH COMPOUNDS FOR THE PREPARATION OF A MEDICINAL PRODUCT AND PROCEDURE FOR THE PREPARATION OF A MEDICINAL PRODUCT.
ES2179960T3 (en) CONSERVATION SOLUTION FOR ORGANS OR FABRICS, OR PARTS OF THE SAME, OF HUMAN OR ANIMAL BEINGS.
ES2176495T3 (en) USE OF AN BRADIQUININE ANTAGONIST, INTENDED TO INDUCE AND / OR STIMULATE THE GROWTH OF HAIRS AND / OR STOP THEIR FALL.
AR026254A1 (en) THE USE OF A CONTROLLED RELEASE PREPARATION FOR THE PREPARATION OF A MEDICINAL PRODUCT TO INCREASE THE DOSE OR SYSTEM EXPOSURE OF A PHARMACO THAT INHIBITS PHOSPHODESTERASE 4
ES2131863T3 (en) DERIVATIVES OF COLCHICINA AND ITS THERAPEUTIC USE.
CO4410174A1 (en) PHARMACEUTICAL PREPARATIONS FOR CEFIXIMA